U.S. Multi-Analyte Point-of-Care Testing Devices Market 2025

Market Outlook

By 2035, the U.S. Multi-Analyte Point-of-Care Testing Devices Market is expected to reach approximately USD 5.88 billion, expanding at an estimated CAGR of 12.25% during the forecast period 2026–2035. The market was valued at approximately USD 1.85 billion in 2025, following expansion from around USD 1.12 billion in 2021, USD 1.29 billion in 2022, USD 1.46 billion in 2023, and USD 1.65 billion in 2024. Values in this report are expressed in USD billions.

For the purpose of this report, the market includes portable, handheld, near-patient, and compact point-of-care systems capable of measuring or identifying multiple analytes, biomarkers, pathogens, or physiological parameters from a single patient specimen or testing workflow. Revenue includes analyzers, readers, instrumentation, proprietary cartridges, reagent panels, test cards, and system-specific consumables. Conventional single-analyte glucose meters and multiplex platforms designed primarily for centralized reference laboratories are excluded.

The U.S. multi-analyte point-of-care testing devices industry is moving from a collection of specialized bedside analyzers toward a broader decentralized diagnostic ecosystem. Clinical demand is increasingly centered on obtaining several clinically actionable results from one sample while the patient is still present. Emergency physicians may require electrolytes, blood gases, glucose, lactate, renal markers, and hematocrit simultaneously. Urgent-care clinicians increasingly need to differentiate influenza, SARS-CoV-2, RSV, and other respiratory pathogens during one encounter. Cardiometabolic programs benefit from platforms that combine HbA1c, lipid, renal, inflammatory, and other risk-related parameters without routing specimens through a central laboratory.

This workflow advantage is strategically important in the United States. U.S. emergency departments record more than 155 million visits in a typical year, including approximately 17.8 million visits resulting in hospital admission and more than 3 million admissions to critical-care units. About 1.7 million U.S. adults develop sepsis annually, while roughly 38 million U.S. adults live with diabetes. These clinical volumes create a large recurring testing environment in which rapid multi-analyte information can change triage, treatment initiation, antimicrobial decisions, disposition, admission, and discharge workflows.

The market is also benefiting from a large provider infrastructure. The United States has approximately 6,100 hospitals, including more than 5,100 community hospitals, in addition to thousands of urgent-care centers, physician-office laboratories, retail clinics, ambulatory facilities, emergency departments, oncology centers, dialysis facilities, and post-acute care locations. The addressable market therefore extends well beyond tertiary hospitals.

The historical market expanded from approximately USD 1.12 billion in 2021 to USD 1.65 billion in 2024 as pandemic-era decentralized testing infrastructure accelerated familiarity with near-patient molecular diagnostics, hospitals strengthened critical-care testing capacity, and manufacturers expanded cartridge-based multi-marker systems. In 2025, market value reached approximately USD 1.85 billion as respiratory multiplex testing became increasingly normalized, blood-gas and chemistry platforms continued replacement cycles, and CLIA-waived multi-target systems expanded into lower-complexity settings.

From 2026 through 2035, value creation is expected to shift increasingly toward platforms that consolidate tests, minimize specimen handling, shorten turnaround time, automate quality control, connect directly with electronic medical records, and provide results that immediately alter clinical management. The central purchasing question for U.S. providers will therefore move beyond analytical accuracy alone toward the total economics of diagnostic decision-making.

Introduction

According to the U.S. Multi-Analyte Point-of-Care Testing Devices Market Report, the market is being shaped by the convergence of decentralized diagnostics, hospital labor constraints, faster treatment pathways, CLIA-waived testing expansion, cartridge-based automation, and growing demand for actionable diagnostic information during a single patient encounter.

Multi-analyte point-of-care testing solves a different clinical problem from conventional laboratory testing. A centralized laboratory is optimized for scale, automation, batching, and broad test menus. Point-of-care testing is optimized for immediacy. Multi-analyte POC systems add another layer of value by generating several related results from one small specimen, potentially eliminating sequential orders, multiple sample collections, specimen transport, and waiting intervals.

This value proposition is particularly important in emergency medicine, intensive care, neonatal care, operating rooms, acute respiratory assessment, cardiometabolic disease management, renal evaluation, infectious-disease triage, and anticoagulation-related workflows. A clinician assessing a critically ill patient may need to understand oxygenation, acid-base balance, electrolytes, glucose, lactate, kidney function, and hematologic status within minutes rather than waiting for several laboratory departments to process separate assays.

Portable blood-analysis platforms already demonstrate the maturity of this model. Current systems can measure more than ten blood gas, electrolyte, and metabolite parameters from a single small-volume specimen and provide results in approximately one minute. At the same time, molecular point-of-care systems are moving rapidly toward broader pathogen differentiation. Contemporary respiratory panels can simultaneously identify multiple viral and bacterial targets, while smaller multiplex assays can differentiate clinically overlapping pathogens such as SARS-CoV-2, influenza A, influenza B, and RSV.

The economics are compelling where testing speed affects treatment or patient flow. A device does not need to be less expensive than the central laboratory on a cost-per-analyte basis to generate economic value. It can justify adoption by reducing emergency department dwell time, accelerating isolation decisions, improving antimicrobial selection, avoiding unnecessary admissions, supporting earlier discharge, reducing duplicate orders, improving operating-room readiness, or allowing physicians to begin treatment before the patient leaves a clinic.

U.S. health systems are consequently evaluating multi-analyte POC devices through total workflow economics. Procurement committees increasingly examine analyzer acquisition cost, cartridge utilization, operator training requirements, quality-control burden, connectivity, middleware compatibility, nursing time, specimen requirements, maintenance, reimbursement, test-menu flexibility, and the consequences of diagnostic delay.

The strongest commercial platforms therefore combine analytical performance with low operational complexity. Devices that require minimal pipetting, automate calibration, use room-temperature cartridges, reduce manual interpretation, provide barcode-based patient identification, transmit results directly to laboratory information systems, and maintain strong operator controls are positioned more favorably than systems requiring laboratory-style expertise.

The addressable opportunity is also broadening outside hospitals. Urgent-care centers, retail health locations, physician-office laboratories, outpatient specialty clinics, rural care sites, skilled nursing facilities, and community health organizations increasingly require diagnostic capability without full central-laboratory infrastructure. Multi-analyte platforms are particularly relevant because one instrument can potentially replace several dedicated testing devices, reducing training, maintenance, inventory, and connectivity complexity.

Key Market Drivers: What’s Fueling the U.S. Multi-Analyte Point-of-Care Testing Devices Market Boom?

The first major growth driver is the economic value of faster clinical decisions. U.S. emergency departments handle more than 155 million visits annually, creating continuous pressure to reduce turnaround time and determine whether patients should be treated, admitted, transferred, isolated, or discharged. Multi-analyte POC testing compresses the interval between specimen collection and decision-making, which becomes especially valuable during periods of emergency department crowding.

Critical-care demand represents another structural driver. Approximately 1.7 million U.S. adults develop sepsis each year, with hundreds of thousands dying during hospitalization or being discharged to hospice. Sepsis management requires rapid assessment of metabolic condition, lactate, organ dysfunction, infection source, respiratory status, and treatment response. Blood gas, electrolyte, metabolite, hematology, and molecular POC systems therefore participate directly in time-sensitive care pathways.

The chronic-disease burden also supports recurring demand. Around 38 million U.S. adults live with diabetes, while cardiovascular disease, chronic kidney disease, obesity, hypertension, and related metabolic conditions affect much larger populations. Multi-parameter platforms that consolidate HbA1c, lipid, renal, glucose, electrolyte, or cardiometabolic information can support decentralized screening and follow-up while reducing dependence on separate laboratory visits.

A fourth driver is respiratory multiplex testing. Influenza, SARS-CoV-2, RSV, and other respiratory pathogens frequently produce overlapping symptoms. Identifying several organisms from one specimen can improve treatment selection, antiviral utilization, infection-control decisions, antibiotic stewardship, and patient counseling. Current U.S. clinical guidance increasingly recognizes the value of multiplex molecular testing when multiple respiratory viruses are circulating.

Regulatory evolution is also strengthening the addressable market. FDA clearance combined with CLIA-waived status can materially expand a platform beyond hospital laboratories into urgent-care centers, physician offices, retail clinics, and other decentralized settings. During 2023–2025, multiple molecular respiratory systems and multi-target assays received CLIA-waived designations, demonstrating that sophisticated multiplex testing can migrate into relatively low-complexity operating environments when device design sufficiently controls analytical risk.

Hospital workforce constraints represent another important factor. Point-of-care testing transfers some diagnostic activity away from centralized laboratories but can create new burdens if devices are difficult to operate or manage. This is why automation matters. Systems with integrated quality checks, operator locking, barcode identification, automated calibration, electronic connectivity, standardized cartridges, and simplified sample preparation can reduce the hidden labor cost associated with decentralized testing.

Health-system consolidation also favors platform standardization. Large integrated delivery networks may operate dozens or hundreds of acute-care, outpatient, urgent-care, and physician-office locations. Standardizing a limited number of point-of-care platforms can reduce training requirements, service contracts, reagent inventories, competency programs, middleware interfaces, and procurement complexity. Manufacturers with scalable enterprise connectivity and broad test menus can therefore secure larger system-level agreements.

Another driver is the movement of care into ambulatory settings. Many diagnostic encounters that historically occurred in hospital outpatient departments are shifting toward lower-cost locations. Urgent-care networks, ambulatory clinics, retail health operators, oncology infusion centers, dialysis providers, and specialty practices need rapid diagnostic capability but generally cannot replicate the staffing or equipment footprint of full-service laboratories. Compact multi-analyte systems fit this economic model.

Finally, the U.S. market benefits from recurring consumable economics. Instruments create installed bases, but proprietary cartridges, test cards, reagent discs, and molecular panels generate continuing revenue. Once a platform is standardized across a health system and integrated with clinical workflows, switching costs can become meaningful. This creates attractive recurring revenue models for manufacturers and increases the strategic importance of placement, connectivity, service reliability, and menu expansion.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. multi-analyte point-of-care testing devices market is increasingly centered on diagnostic density: generating more clinically useful information from smaller specimens, simpler workflows, and shorter turnaround times.

Microfluidics is one of the enabling technologies. Modern cartridges can route extremely small sample volumes through multiple sensing or reaction zones, allowing several measurements to occur within one disposable device. This supports compact system architectures while reducing the need for multiple blood draws and separate assay preparation.

Integrated blood analysis remains a major innovation category. New-generation handheld and portable systems combine blood gases, electrolytes, metabolites, hematocrit, renal parameters, and calculated clinical values. Some commercially established platforms can analyze approximately thirteen measured parameters from one test card and return results in less than one minute. The competitive emphasis is increasingly on room-temperature cartridge stability, sample-volume reduction, connectivity, and reduced maintenance rather than on analytical capability alone.

Multiplex molecular testing represents the fastest-moving technology frontier. Compact PCR and other nucleic-acid-amplification systems can simultaneously differentiate multiple respiratory organisms using near-patient workflows. FDA-cleared and CLIA-waived respiratory panels now range from focused four-pathogen configurations to broader panels capable of identifying substantially more targets.

The clinical value of multiplexing is evolving from simply “more results” toward more targeted diagnostic pathways. Broad panels can be valuable when the differential diagnosis is wide, whereas smaller syndromic panels can provide better economics where clinicians only need to distinguish several high-probability pathogens. Manufacturers are therefore developing tiered menus rather than assuming that the largest possible panel is always commercially optimal.

Multi-marker immunoassay testing is another area of opportunity. Cardiovascular, inflammatory, infectious, renal, and metabolic conditions frequently require interpretation of several biomarkers rather than one marker in isolation. As sensors become more sensitive and cartridges more automated, POC platforms can increasingly support several immunoassays from the same specimen.

Artificial intelligence and software are becoming an invisible competitive layer. The next generation of systems will increasingly use software for quality control, result flagging, operator guidance, longitudinal comparison, clinical decision support, instrument management, predictive maintenance, and fleet-level utilization analysis. For health systems, the value of a platform may eventually depend as much on its data architecture as on its analyzer hardware.

Connectivity is becoming essential rather than optional. Hospital buyers increasingly expect bidirectional connectivity, automatic patient identification, centralized device management, operator credentialing, remote quality-control monitoring, cybersecurity safeguards, and integration with laboratory and electronic health record systems. An analyzer that produces accurate results but creates manual documentation burden can lose procurement evaluations to a better-connected competitor.

Sample simplification is another major innovation direction. Fingerstick and low-volume capillary workflows can expand testing outside traditional laboratory environments, although analytical performance must remain appropriate for each intended use. Manufacturers that minimize specimen processing and eliminate centrifugation or complex transfer steps can widen their usable customer base.

Over the forecast period, innovation will increasingly focus on configurable multi-analyte cartridges. Instead of requiring users to purchase completely different systems for different clinical scenarios, platform developers are moving toward common instruments with application-specific disposable panels. This architecture improves manufacturer economics while allowing hospitals to expand menus without repeatedly replacing capital equipment.

Segmentation Insights

The U.S. Multi-Analyte Point-of-Care Testing Devices Market is segmented on the basis of product type, test panel, technology, end user, and region.

By Product Type

Handheld Multi-Analyte Analyzers

Handheld analyzers represent one of the most clinically established product categories because they can move with the clinician to the bedside. These systems are particularly important in emergency departments, intensive care units, operating rooms, neonatal care, transport medicine, and hospital rapid-response teams. Their primary value proposition is immediate access to several blood parameters without requiring specimen transport.

Competition in this segment is increasingly influenced by cartridge stability, sample size, instrument weight, battery performance, wireless connectivity, data security, and the breadth of calculated parameters. Replacement demand from existing hospital fleets provides a stable revenue base, while newer connected platforms support premium upgrades.

Portable and Compact Benchtop Systems

Portable and compact benchtop platforms serve environments where slightly higher throughput is required but full central-laboratory infrastructure is unnecessary. Emergency departments, urgent-care centers, physician-office laboratories, outpatient clinics, ambulatory facilities, and satellite laboratories are important users.

These systems can support a broader menu or higher daily testing volume than handheld devices while preserving rapid turnaround. Their strategic advantage is particularly strong when an organization wants to consolidate several dedicated analyzers into one standardized workstation.

Cartridge-Based Molecular Multiplex Systems

Cartridge-based molecular systems are expected to generate the fastest product-category growth through 2035. They automate nucleic-acid extraction, amplification, detection, and interpretation inside closed consumables, allowing non-specialist users to perform sophisticated testing near the patient.

Respiratory infections are currently the largest commercial use case, but sexually transmitted infections, gastrointestinal infections, antimicrobial-resistance markers, and other syndromic applications provide significant expansion potential.

Multi-Analyte Immunoassay Platforms

Multi-analyte immunoassay devices measure multiple proteins, antigens, antibodies, hormones, or other biomarkers from one sample. Cardiometabolic risk, cardiac assessment, infectious disease, inflammation, and chronic-disease monitoring are attractive applications.

The commercial challenge remains balancing panel breadth with reimbursement and clinical necessity. Platforms that align specific biomarker combinations with defined clinical decisions will generally have stronger utilization economics than broad panels that generate unnecessary results.

Integrated POC Platforms and Proprietary Consumables

Integrated systems combine an analyzer with proprietary cartridges, discs, panels, or test cards that create recurring revenue. This segment is strategically important because consumable utilization determines lifetime customer value.

Manufacturers increasingly use instrument placement, reagent rental, service agreements, enterprise contracts, and volume-linked pricing to accelerate adoption. For health systems, the evaluation therefore extends beyond instrument acquisition cost to total cost per reportable result.

By Test Panel

Blood Gas, Electrolyte and Metabolite Panels

Blood gas, electrolyte, and metabolite testing represents one of the largest established multi-analyte applications. Common parameters include pH, pCO2, pO2, sodium, potassium, ionized calcium, chloride, glucose, lactate, hematocrit, creatinine, blood urea nitrogen, and related calculated values.

Demand is concentrated in emergency medicine, intensive care, respiratory care, neonatal units, anesthesia, surgery, and critical transport. Because results can influence ventilation, fluids, electrolyte replacement, glucose management, renal assessment, and sepsis treatment, turnaround time has direct clinical value.

Multiplex Infectious-Disease Panels

Multiplex infectious-disease testing is expected to be the fastest-growing panel category. Respiratory testing currently leads adoption because influenza, SARS-CoV-2, RSV, and other pathogens frequently circulate simultaneously and present with similar symptoms.

Focused multiplex assays can support urgent-care economics, while larger syndromic panels are more attractive to emergency departments and hospitals handling medically complex patients. Future growth will expand into gastrointestinal, sexual-health, bloodstream, and other infectious-disease applications as platforms become simpler and more decentralized.

Cardiometabolic Multi-Marker Panels

Cardiometabolic testing includes combinations of lipid parameters, glucose-related markers, renal markers, cardiac biomarkers, and other risk-related measurements. The segment benefits from high U.S. prevalence of diabetes, cardiovascular disease, hypertension, obesity, and chronic kidney disease.

Physician practices, community health centers, urgent-care locations, pharmacies, and employer-health programs are increasingly relevant as chronic-disease management becomes more decentralized.

Hematology and Coagulation Panels

Near-patient hematology and coagulation systems support blood-count assessment, bleeding management, anticoagulation monitoring, surgical workflows, oncology care, and emergency evaluation. The opportunity is especially attractive where immediate results determine whether a procedure can proceed or whether treatment needs adjustment.

Compact systems capable of reducing manual sample preparation and providing automated quality controls can gain penetration in smaller facilities that cannot maintain large hematology laboratories.

Multi-Marker Specialty and Emerging Panels

Emerging panels include combinations used in inflammation assessment, renal disease, women’s health, toxicology, therapeutic monitoring, and specialty diagnostics. Commercial adoption will depend on clinical evidence demonstrating that receiving the combined markers immediately changes patient management.

This category could become substantially larger as microfluidic, biosensor, and digital technologies make customized multi-marker testing economically practical.

By Technology

Electrochemical and Biosensor-Based Testing

Electrochemical sensing remains highly important for blood gases, electrolytes, glucose, lactate, and other chemistry measurements. The technology is established, rapid, compact, and compatible with small sample volumes.

Future differentiation will come from sensor stability, cartridge manufacturing consistency, calibration automation, interference management, and integration of additional analytes.

Molecular Diagnostics and Nucleic-Acid Amplification

Molecular technology is the fastest-growing technology segment because it combines strong analytical sensitivity with increasingly automated near-patient workflows. Compact PCR and rapid nucleic-acid-amplification platforms are particularly important for respiratory and other infectious diseases.

Expansion of CLIA-waived systems is expected to increase accessibility outside traditional molecular laboratories.

Immunoassay Technology

Fluorescent, chemiluminescent, enzyme-linked, and other immunoassay methods support a wide range of proteins and disease markers. Multi-analyte POC immunoassays have significant potential in cardiac assessment, infection, inflammation, metabolic disease, and specialty applications.

Clinical adoption will depend on precision, multiplex capability, calibration stability, and alignment with reimbursement pathways.

Microfluidic Lab-on-Cartridge Technology

Microfluidics allows specimen processing, reagent movement, reaction control, and detection within a compact disposable cartridge. It is one of the most important enabling technologies for future multi-analyte systems because it can reduce instrument complexity while increasing diagnostic density.

Lab-on-cartridge architectures are expected to enable new combinations of chemistry, molecular, immunological, and cellular testing over the forecast period.

Optical, Imaging and Hybrid Detection Technologies

Optical and hybrid detection methods are used in fluorescence, absorbance, cell analysis, immunoassays, and molecular diagnostics. Advances in miniature optics, cameras, LEDs, and computational interpretation are making sophisticated detection possible in increasingly compact instruments.

Hybrid platforms capable of combining multiple sensing modalities may eventually expand the range of analytes measurable from a single disposable cartridge.

By End User

Hospitals and Health Systems

Hospitals and integrated health systems represent the largest end-user category. Emergency departments, ICUs, operating rooms, neonatal units, cardiac services, respiratory services, and satellite laboratories generate high test volumes and require rapid results.

Large health systems increasingly procure platforms through enterprise contracts and expect centralized device management, connectivity, clinical education, uptime guarantees, cybersecurity support, and standardized consumable pricing.

Urgent-Care and Retail Clinics

Urgent-care and retail clinics represent one of the highest-growth customer groups, particularly for multiplex infectious-disease testing. Their economic model depends on completing diagnosis and treatment during one visit.

CLIA-waived systems with minimal hands-on time, simple specimen collection, automated interpretation, and rapid turnaround have particularly strong potential.

Physician-Office Laboratories

Primary-care, cardiology, endocrinology, nephrology, pulmonology, women’s health, and other specialty practices represent an expanding market for multi-analyte systems.

These users generally prioritize simplicity, reimbursement predictability, small footprints, modest capital requirements, and low maintenance. Platforms that support immediate therapeutic decisions can improve both patient convenience and practice workflow.

Ambulatory, Specialty and Post-Acute Care Facilities

Ambulatory surgery centers, dialysis centers, oncology facilities, skilled nursing facilities, rehabilitation centers, and other specialty settings use rapid testing where treatment cannot easily wait for an external laboratory.

The opportunity is strongest when testing is directly linked to procedural readiness, drug administration, acute deterioration, renal status, infection management, or transfer decisions.

Community, Mobile and Decentralized Care

Community health centers, mobile clinics, rural facilities, public-health programs, employer clinics, pharmacies, and other decentralized locations represent a smaller but strategically important end-user category.

Multi-analyte devices can provide greater value than multiple single-purpose instruments because these facilities often operate with limited staff, space, and technical support. CLIA-waived status will remain a critical adoption catalyst.

Regional Insights: Where the Market is Growing Fastest

Regional performance in the U.S. Multi-Analyte Point-of-Care Testing Devices Market differs according to population scale, emergency-care utilization, hospital concentration, chronic-disease burden, urgent-care penetration, laboratory workforce availability, academic medical center density, technology adoption, and the concentration of decentralized healthcare networks.

South

The South represents the largest regional market, valued at approximately USD 0.68 billion in 2025 and expected to reach about USD 2.16 billion by 2035. The region benefits from high population growth, a substantial burden of diabetes and cardiometabolic disease, large hospital networks, expanding urgent-care infrastructure, and significant rural healthcare requirements.

Texas is the largest strategic state market in the South and one of the most important in the country. Houston, Dallas-Fort Worth, Austin, and San Antonio contain high-volume hospitals and integrated health systems capable of supporting enterprise-scale POC deployments. Texas also has extensive urgent-care, rural, emergency, and community-health networks, making it attractive for both sophisticated multiplex molecular systems and portable blood-analysis devices.

Florida is another critical market because of its large and older population. Acute respiratory disease, cardiometabolic conditions, emergency utilization, and chronic-disease management support multi-analyte testing across hospitals, physician practices, senior-care facilities, urgent-care networks, and ambulatory settings.

Georgia and North Carolina combine population growth with major academic and regional hospital systems. Atlanta, Charlotte, Raleigh-Durham, and other metropolitan areas are attractive launch markets for connected diagnostic systems. North Carolina additionally benefits from its life-sciences ecosystem and concentration of clinical research expertise.

Virginia and Maryland have sophisticated health systems, dense suburban populations, and proximity to federal research and healthcare institutions. Tennessee is supported by major hospital operators and regional referral networks, while South Carolina continues to benefit from population migration and health-system expansion.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia, and Oklahoma carry substantial chronic-disease burdens and meaningful rural access challenges. These states create a particularly strong use case for compact multi-analyte testing because centralized laboratory access can be slower outside major metropolitan areas. Cost sensitivity is higher, however, which favors systems with predictable cartridge economics and low maintenance.

Delaware has a smaller absolute market but benefits from Northeast corridor healthcare access, while the state’s hospital networks and outpatient facilities support steady demand.

The South is expected to remain the largest regional market throughout the forecast period because population growth and decentralized healthcare expansion will offset greater pricing pressure. Health systems that standardize multi-analyte testing across hospitals, freestanding emergency departments, urgent-care centers, and physician offices will be particularly important customers.

West

The West represented approximately USD 0.46 billion in 2025 and is projected to reach around USD 1.59 billion by 2035, making it the fastest-growing regional market at an estimated CAGR of approximately 13.2%.

California dominates regional demand. Its large population, extensive academic medical center network, integrated health systems, technology-oriented providers, and strong diagnostics innovation ecosystem create favorable conditions for premium multi-analyte systems. California is especially important for early adoption of molecular multiplexing, microfluidics, digital connectivity, and decentralized testing workflows.

Washington and Oregon have sophisticated integrated delivery networks and strong adoption of digital health infrastructure. These markets tend to place significant emphasis on interoperability, quality management, data connectivity, and standardized enterprise platforms.

Arizona and Nevada are high-growth markets because of rapid population expansion and large older-adult populations. Phoenix, Tucson, Las Vegas, and surrounding health networks are increasing hospital, urgent-care, and ambulatory capacity, supporting demand for rapid chemistry and infectious-disease testing.

Colorado and Utah combine growing populations with advanced healthcare systems and strong technology adoption. Utah is also strategically important because of its molecular-diagnostics and biotechnology ecosystem. Colorado’s major metropolitan health systems provide attractive settings for integrated multi-analyte deployment.

New Mexico has particular need for rural and decentralized diagnostics because of large geographic distances and uneven access to centralized testing. Idaho and Montana have similar rural-care dynamics, though absolute revenue potential is smaller.

Wyoming and Alaska are small markets by population but demonstrate the core value proposition of portable diagnostic technology: providing actionable results where transport to a full laboratory may introduce meaningful delay. Hawaii faces island-specific logistical constraints that similarly strengthen the role of decentralized diagnostic capacity.

The West is expected to gain national share through 2035 because it combines population growth, high technology acceptance, digitally mature providers, and a strong innovation ecosystem. Manufacturers introducing AI-enabled, connected, or cartridge-based platforms often have opportunities to establish early reference sites in this region.

Northeast

The Northeast accounted for approximately USD 0.43 billion in 2025 and is expected to approach USD 1.32 billion by 2035. The region does not have the population growth of the South or West, but it remains one of the most influential U.S. markets for advanced diagnostics.

New York represents the largest Northeast market because of its population size, dense hospital infrastructure, academic centers, emergency-care volume, and broad outpatient network. Large health systems in New York City and surrounding areas can influence national procurement decisions through technology evaluation and clinical evidence generation.

Massachusetts is disproportionately important relative to its population. Boston’s academic hospitals, biotechnology ecosystem, laboratory expertise, and clinical research infrastructure make the state an attractive early-adoption environment for molecular and multi-marker diagnostic technology.

Pennsylvania provides a large and diversified testing base across Philadelphia, Pittsburgh, and regional health systems. Its mix of academic centers, community hospitals, urgent-care locations, and older populations supports both acute-care and ambulatory testing.

New Jersey combines dense population, major health systems, pharmaceutical industry presence, and strong physician-office infrastructure. Connecticut has sophisticated hospital networks and high per-capita healthcare spending, supporting premium diagnostic adoption.

Maine, New Hampshire, and Vermont have smaller populations but important rural-care requirements. Portable and easy-to-operate systems can improve access where transporting specimens to centralized facilities creates delays. Rhode Island is compact but has a concentrated hospital market with strong academic affiliations.

The Northeast is likely to remain an evidence-intensive procurement environment. Manufacturers often face rigorous value-analysis requirements but can gain national credibility when their technologies are adopted by leading academic centers in the region.

Midwest

The Midwest represented approximately USD 0.28 billion in 2025 and is expected to reach approximately USD 0.81 billion by 2035. Growth is expected to be slower than in the South and West but supported by large established hospital networks, regional referral systems, chronic-disease burden, and rural diagnostic needs.

Illinois is the region’s largest market, led by Chicago’s academic hospitals, large integrated health systems, emergency departments, and outpatient networks. The state offers opportunities for both premium hospital-based devices and decentralized systems serving suburban and rural populations.

Ohio and Michigan have large health systems, significant acute-care utilization, and substantial cardiometabolic disease burden. These factors support blood-analysis, respiratory multiplex, and chronic-disease testing platforms.

Minnesota is strategically important because of its mature medical-device ecosystem and sophisticated provider organizations. The state’s integrated care models create favorable conditions for connected diagnostic systems and enterprise standardization.

Indiana and Wisconsin provide stable hospital and ambulatory demand. Missouri has major healthcare hubs in St. Louis and Kansas City, while Iowa and Kansas are important for regional hospital networks and rural healthcare delivery.

Nebraska, North Dakota, and South Dakota have smaller absolute markets but strong use cases for portable diagnostic testing because patients and specimens may travel substantial distances. Multi-analyte POC systems can improve local decision-making and reduce unnecessary transfers.

The Midwest will remain an important market for suppliers capable of delivering reliability, strong service coverage, competitive cartridge economics, remote device management, and practical clinical education rather than relying solely on premium technology positioning.

Key Market Players

The U.S. Multi-Analyte Point-of-Care Testing Devices Competitive Landscape is moderately concentrated at the platform level but fragmented across clinical applications. No single manufacturer dominates every technology category because blood analysis, molecular multiplexing, immunoassay, hematology, coagulation, chemistry, and infectious-disease testing require different technical competencies.

Abbott Laboratories remains one of the most strategically important competitors through its i-STAT ecosystem and broader POC diagnostics portfolio. Its installed base, hospital relationships, cartridge model, and connectivity infrastructure provide significant competitive advantages.
Siemens Healthineers has a strong position in near-patient blood analysis through the epoc platform, which can measure multiple blood gas, electrolyte, and metabolite parameters using a single test card.
bioMérieux/BioFire Diagnostics has become an important competitor in decentralized multiplex molecular diagnostics through the BIOFIRE SPOTFIRE platform and expanding respiratory and respiratory/sore-throat menus.
Roche Diagnostics participates through the cobas Liat molecular platform and other decentralized diagnostic technologies. Its expanding multiplex respiratory menu strengthens its position in urgent-care and physician-office testing.
Danaher Corporation/Cepheid is highly relevant through GeneXpert and GeneXpert Xpress molecular systems, which have established significant U.S. infectious-disease testing infrastructure.
QuidelOrtho Corporation maintains a broad position in rapid and near-patient diagnostics, with immunoassay and molecular capabilities applicable to respiratory and other infectious diseases.
Werfen is an important competitor in acute-care diagnostics, particularly blood gas and hemostasis-related environments, supported by established hospital relationships.
Radiometer Medical maintains a strong presence in acute-care blood gas testing, particularly in critical-care and hospital environments where rapid physiological assessment is required.
Nova Biomedical competes in hospital point-of-care testing through connected blood-analysis, glucose, ketone, creatinine, and related technologies and has an established position in critical-care workflows.
QIAGEN participates through syndromic molecular diagnostic systems including QIAstat-Dx, providing an important competitive presence in multiplex infectious-disease testing.
DiaSorin participates through molecular diagnostic platforms and acquired multiplex capabilities, giving it exposure to respiratory and other multi-target applications.
Becton, Dickinson and Company has a substantial diagnostics footprint and point-of-care presence, particularly in infectious-disease and specimen-management workflows.
Sysmex Corporation participates in compact hematology and POC-oriented blood-count testing, creating opportunities in physician offices and decentralized settings.
PixCell Medical competes in compact hematology through cartridge-based platforms designed to provide rapid blood-count results close to the patient.
HORIBA Medical has a position in compact hematology and clinical chemistry instrumentation relevant to decentralized and smaller-laboratory environments.
EKF Diagnostics participates in point-of-care and near-patient analyzers across hemoglobin, HbA1c, glucose, lactate, and related testing categories.
ACON Laboratories competes in decentralized diagnostics including urinalysis and rapid-testing systems and is positioned to participate in increasingly connected multi-parameter workflows.
Sekisui Diagnostics has a significant diagnostics portfolio spanning rapid tests, chemistry, and infectious-disease applications.
Trinity Biotech participates in point-of-care and specialty diagnostic testing, including chronic-disease and infectious-disease applications.
Thermo Fisher Scientific has broad diagnostic and assay-development capabilities and can participate indirectly and directly in emerging multi-analyte technology ecosystems.
Zoetis/Abaxis has relevant compact chemistry platform expertise, particularly through portable rotor-based analysis technology, although its strongest commercial orientation is veterinary diagnostics.
LumiraDx technology assets, now associated with Roche following strategic transactions, remain relevant to the evolution of microfluidic multi-assay POC architectures.
Visby Medical represents an important emerging molecular POC competitor with compact cartridge-based testing designed for decentralized infectious-disease applications.
Nuclein represents another emerging participant in rapid molecular POC testing with simplified instrument and cartridge architectures.
MeMed and other biomarker-driven diagnostic developers illustrate the next competitive frontier, in which multi-marker host-response signatures may complement or compete with pathogen-specific testing.

Competitive advantage through 2035 will increasingly depend on installed-base penetration, recurring cartridge economics, breadth of clinically useful menus, CLIA-waived status, connectivity, evidence generation, service infrastructure, manufacturing reliability, and the ability to demonstrate measurable workflow improvement.

Recent Developments

Recent developments in the U.S. Multi-Analyte Point-of-Care Testing Devices Market demonstrate accelerating regulatory acceptance of multiplex decentralized diagnostics.

During 2025, the FDA granted CLIA-waived status to a cobas Liat molecular test capable of detecting SARS-CoV-2, influenza A/B, and RSV. The significance extends beyond one assay: a four-pathogen molecular result can now be delivered using a simplified near-patient workflow in settings that do not operate high-complexity molecular laboratories.

The BIOFIRE SPOTFIRE platform has also expanded the definition of point-of-care multiplexing. Its respiratory and respiratory/sore-throat panels can identify multiple pathogens using integrated molecular workflows, and additional CLIA-waived configurations expanded during 2024 and 2025. These developments create a competitive spectrum ranging from focused respiratory panels to significantly broader syndromic testing.

Cepheid’s GeneXpert Xpress ecosystem continues to expand decentralized molecular testing through cartridge-based assays covering combinations of SARS-CoV-2, influenza, and RSV alongside other infectious-disease applications. Installed-base leverage is particularly important because health systems can add assays to existing instrument infrastructure.

Acute-care blood testing is simultaneously undergoing a quieter but economically important modernization cycle. Hospitals are moving toward connected handheld systems, reduced-maintenance analyzers, room-temperature consumables, smaller blood-volume requirements, and centralized fleet management. These improvements matter particularly in neonatal and critical-care environments where repeated specimen collection can create clinical burden.

The market is also seeing greater convergence between molecular diagnostics and traditional POC device economics. Historically, molecular testing required specialized laboratory personnel and infrastructure. Closed cartridges, automated sample preparation, internal controls, and simplified interfaces are steadily reducing those barriers.

A further development is growing health-system emphasis on device standardization. Procurement decisions increasingly favor platforms that can be deployed across several care settings while remaining centrally governed by the laboratory or point-of-care testing department. This improves quality management and strengthens enterprise purchasing leverage.

Over the next several years, product development is expected to extend beyond respiratory multiplex testing toward broader infectious-disease syndromes, host-response markers, cardiometabolic panels, kidney assessment, and integrated multi-marker decision support.

Conclusion

The U.S. Multi-Analyte Point-of-Care Testing Devices Market Size & Share is positioned for substantial expansion from approximately USD 1.85 billion in 2025 to USD 5.88 billion by 2035, reflecting an estimated 12.25% CAGR during 2026–2035.

The industry’s growth is not simply the result of greater diagnostic testing volume. The more important shift is the economic migration of diagnostic information toward the patient. U.S. providers increasingly need several actionable results during the clinical encounter rather than several hours later. This creates a structural advantage for devices capable of consolidating analytes, reducing specimen handling, and turning testing into an immediate decision-support function.

Multiplex molecular diagnostics will be one of the strongest growth engines, supported by expanding respiratory testing, broader CLIA-waived availability, automated cartridge systems, and increasing comfort with decentralized nucleic-acid testing. Blood gas, electrolyte, chemistry, and metabolite platforms will remain the largest established acute-care foundation because their results are deeply integrated into emergency, ICU, surgical, neonatal, and critical-care workflows.

Microfluidic and biosensor innovation will broaden the market further by allowing manufacturers to extract more diagnostic information from smaller specimens. The long-term opportunity extends beyond conventional analyzers toward integrated clinical decision systems combining disposable cartridges, software, connectivity, quality management, and interpretation.

Hospitals and health systems will remain the largest customers, but some of the strongest incremental growth will occur in urgent-care networks, physician-office laboratories, retail clinics, specialty centers, rural care, and other decentralized environments. CLIA-waived status will be especially important for accessing these sites.

Regionally, the South is expected to retain the largest share because of population scale, hospital expansion, chronic-disease burden, and rapid growth in outpatient care. The West is expected to record the fastest growth because of technology adoption, population migration, advanced health-system infrastructure, and diagnostic innovation. The Northeast will remain strategically influential through its academic centers and early-adoption behavior, while the Midwest will provide stable demand supported by established health systems and rural diagnostic requirements.

At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Massachusetts, Washington, Arizona, Michigan, New Jersey, Virginia, Tennessee, Minnesota, Colorado, Maryland, and Indiana represent particularly important commercial markets because they combine population, healthcare infrastructure, acute-care volumes, outpatient networks, and advanced diagnostic adoption.

For manufacturers, the next competitive cycle will be defined less by whether a system can technically measure multiple analytes and more by whether those measurements create actionable clinical value at an acceptable total cost.

Successful platforms will need to answer several procurement questions simultaneously: Can the device shorten treatment decisions? Can it eliminate separate orders or instruments? Can non-laboratory personnel operate it reliably? Can the laboratory govern quality centrally? Can results enter the electronic health record without manual intervention? Can cartridges remain stable throughout distributed networks? Can the manufacturer maintain reliable supply? Can the clinical benefit justify the cost of each panel?

These requirements favor companies that combine instrument engineering with assay development, informatics, clinical evidence, regulatory execution, field service, and enterprise contracting. They also create opportunities for focused innovators capable of solving one high-value workflow more effectively than broad incumbent platforms.

The U.S. Multi-Analyte Point-of-Care Testing Devices industry is therefore moving toward a platform-based model in which diagnostic density, operational simplicity, connectivity, and speed determine commercial value. By 2035, the most successful systems will not simply perform multiple tests close to the patient; they will help U.S. healthcare organizations make faster decisions with fewer devices, fewer workflow steps, and greater control over the total economics of diagnosis.

TABLE OF CONTENT

1. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Multi-Analyte POC Device Manufacturers
1.6.2. Assay, Reagent, Cartridge and Biosensor Suppliers
1.6.3. Component and Contract Manufacturing Organizations
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Urgent-Care Centers and Physician-Office Laboratories
1.6.6. Retail, Community and Decentralized Care Providers
1.6.7. Group Purchasing Organizations and Diagnostic Distributors
1.6.8. Payers, FDA, CMS, CLIA Authorities and Clinical Decision-Makers

What this section provides: This section defines the U.S. multi-analyte point-of-care testing devices market boundary, revenue scope, methodology, assumptions, included technologies, and stakeholder ecosystem so clients understand how market estimates and forecasts are developed and validated.

2. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.10. Key Clinical and Commercial Adoption Hotspots

What this section provides: This section gives decision-makers a concise view of market size, historical development, forecast growth, leading diagnostic platforms, high-growth applications, competitive intensity, and priority commercial opportunities through 2035.

3. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Growing Demand for Rapid Multi-Parameter Clinical Decision-Making
3.1.2. Expansion of Decentralized and Near-Patient Diagnostic Testing
3.1.3. Rising Adoption of Multiplex Respiratory and Infectious-Disease Testing
3.1.4. Increasing Emergency, Critical-Care and Acute-Care Diagnostic Demand
3.1.5. High U.S. Diabetes, Cardiometabolic and Chronic Disease Burden
3.1.6. Expansion of CLIA-Waived Multi-Analyte Testing Platforms
3.1.7. Laboratory Workforce Constraints and Need for Workflow Automation
3.1.8. Hospital and IDN Standardization of Connected POC Testing Platforms
3.2. Restraints and Their Impact Analysis
3.2.1. High Per-Test Cost of Proprietary Cartridges and Multiplex Panels
3.2.2. Reimbursement Variability Across Multi-Analyte Testing Applications
3.2.3. Point-of-Care Quality Control and Operator Competency Requirements
3.2.4. Platform Lock-In and Proprietary Consumable Dependence
3.2.5. Data Integration and Cybersecurity Requirements
3.2.6. Risk of Low-Value Testing and Unnecessary Broad-Panel Utilization
3.3. Opportunities and Their Impact Analysis
3.3.1. Expansion of CLIA-Waived Multiplex Molecular Testing
3.3.2. Microfluidic Lab-on-Cartridge Platforms
3.3.3. Multi-Marker Cardiometabolic and Acute-Care Testing
3.3.4. Decentralized Testing in Urgent-Care and Physician-Office Settings
3.3.5. Rural and Community-Based Multi-Analyte Diagnostics
3.3.6. AI-Assisted Interpretation and Clinical Decision Support
3.3.7. Enterprise-Wide Connected POC Device Networks
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Central Laboratory-Equivalent Analytical Performance
3.4.2. Managing Large Distributed Device Fleets
3.4.3. Cartridge Supply Reliability and Inventory Optimization
3.4.4. Demonstrating Clinical Utility for Expanded Multi-Marker Panels
3.4.5. Achieving Favorable Health-Economic Evidence
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Point-of-Care Test Turnaround-Time Value Analysis
3.8. Hospital Capital Procurement Behavior Analysis
3.9. Consumables and Recurring Revenue Economics Analysis
3.10. POC Coordinator and Laboratory Governance Impact Analysis

What this section provides: This section explains the clinical, economic, regulatory, reimbursement, workflow, procurement, and technology forces shaping U.S. demand while identifying commercial upside, adoption barriers, and execution risks for market participants.

4. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Analyzer, Cartridge and Reagent Pricing Analysis
4.5. Value Chain & Supply Chain Analysis
4.6. Diagnostic Cartridge and Reagent Manufacturing Ecosystem
4.7. Impact of Digitalization and Connected Point-of-Care Testing
4.8. Application & Innovation Landscape
4.9. FDA Regulatory Framework Analysis
4.9.1. 510(k) Pathway
4.9.2. De Novo Classification Pathway
4.9.3. Premarket Approval Considerations
4.9.4. CLIA Waiver Pathway
4.9.5. Quality System and Post-Market Requirements
4.10. CMS Reimbursement and Coverage Landscape
4.11. CPT Coding and Payment Considerations
4.12. CLIA Regulatory and Testing Complexity Landscape
4.13. Import/Export Restrictions & Tariff Impact
4.14. Government Initiatives and Public Health Programs
4.15. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.16. Hospital Value Analysis Committee Decision Framework
4.17. Point-of-Care Governance and Laboratory Oversight Framework
4.18. Device Connectivity, LIS/EHR Integration and Cybersecurity Analysis

What this section provides: This section gives clients a complete view of the U.S. operating environment, including FDA and CLIA requirements, reimbursement, pricing, cartridges and consumables, supply-chain exposure, digital integration, procurement governance, and competitive industry structure.

5. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Handheld Multi-Analyte Analyzers
5.1.2.1. Blood Gas and Critical-Care Handheld Analyzers
5.1.2.2. Chemistry and Electrolyte Handheld Analyzers
5.1.2.3. Multi-Parameter Portable Blood Analysis Systems
5.1.3. Portable and Compact Benchtop Multi-Analyte Systems
5.1.3.1. Compact Clinical Chemistry Platforms
5.1.3.2. Portable Blood Gas and Electrolyte Systems
5.1.3.3. Multi-Parameter Near-Patient Workstations
5.1.4. Cartridge-Based Multiplex Molecular Systems
5.1.4.1. Focused Multiplex Molecular Platforms
5.1.4.2. Syndromic Multiplex Molecular Platforms
5.1.4.3. CLIA-Waived Molecular POC Systems
5.1.5. Multi-Analyte Immunoassay Platforms
5.1.5.1. Fluorescence-Based Systems
5.1.5.2. Chemiluminescence-Based Systems
5.1.5.3. Multi-Marker Cartridge Immunoassay Systems
5.1.6. Integrated Lab-on-Cartridge and Multi-Parameter Platforms
5.1.6.1. Microfluidic Cartridge Platforms
5.1.6.2. Disc-Based Multi-Analyte Systems
5.1.6.3. Hybrid Multi-Technology Platforms

What this section provides: This section identifies the multi-analyte POC device formats expected to generate the highest U.S. revenue contribution, installed-base expansion, recurring cartridge utilization, and strongest growth through 2035.

6. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By Test Panel

6.1. Overview
6.1.1. Segment Share Analysis, By Test Panel, 2025 & 2035 (%)
6.1.2. Blood Gas, Electrolyte and Metabolite Panels
6.1.2.1. Blood Gas Parameters
6.1.2.2. Electrolytes
6.1.2.3. Glucose and Lactate
6.1.2.4. Renal and Metabolic Parameters
6.1.2.5. Hematocrit and Related Calculated Parameters
6.1.3. Multiplex Infectious-Disease Panels
6.1.3.1. Respiratory Pathogen Panels
6.1.3.2. SARS-CoV-2/Influenza/RSV Combination Panels
6.1.3.3. Gastrointestinal Pathogen Panels
6.1.3.4. Sexual Health and STI Panels
6.1.3.5. Other Syndromic Infectious-Disease Panels
6.1.4. Cardiometabolic Multi-Marker Panels
6.1.4.1. Lipid Panels
6.1.4.2. Diabetes and Glycemic Assessment Panels
6.1.4.3. Cardiac Biomarker Combinations
6.1.4.4. Renal and Cardiometabolic Risk Panels
6.1.5. Hematology and Coagulation Panels
6.1.5.1. Complete and Differential Blood Count Parameters
6.1.5.2. Coagulation and Anticoagulation Parameters
6.1.5.3. Perioperative Hematology Panels
6.1.6. Specialty and Emerging Multi-Marker Panels
6.1.6.1. Inflammatory Marker Panels
6.1.6.2. Renal Function Panels
6.1.6.3. Women’s Health Panels
6.1.6.4. Toxicology and Drug Monitoring Panels
6.1.6.5. Host-Response and Emerging Biomarker Panels

What this section provides: This section evaluates demand by multi-analyte test configuration and helps clients identify the clinical panels with the strongest testing volumes, cartridge revenue opportunity, decentralized testing potential, and forecast growth.

7. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Health Systems
7.1.2.1. Emergency Departments
7.1.2.2. Intensive and Critical Care Units
7.1.2.3. Operating Rooms and Perioperative Care
7.1.2.4. Neonatal and Pediatric Critical Care
7.1.2.5. Hospital Satellite Laboratories
7.1.3. Urgent-Care Centers and Retail Clinics
7.1.3.1. Independent Urgent-Care Centers
7.1.3.2. Health System-Affiliated Urgent-Care Networks
7.1.3.3. Retail Health Clinics
7.1.4. Physician-Office Laboratories
7.1.4.1. Primary-Care Practices
7.1.4.2. Cardiology Practices
7.1.4.3. Endocrinology and Diabetes Practices
7.1.4.4. Pulmonology and Infectious-Disease Practices
7.1.4.5. Other Specialty Physician Practices
7.1.5. Ambulatory, Specialty and Post-Acute Care Facilities
7.1.5.1. Ambulatory Surgery Centers
7.1.5.2. Dialysis Centers
7.1.5.3. Oncology and Infusion Centers
7.1.5.4. Skilled Nursing and Post-Acute Facilities
7.1.5.5. Specialty Outpatient Centers
7.1.6. Community, Mobile and Decentralized Care Settings
7.1.6.1. Community Health Centers
7.1.6.2. Rural and Critical Access Facilities
7.1.6.3. Mobile Health Units
7.1.6.4. Public Health Testing Sites
7.1.6.5. Employer and Occupational Health Clinics

What this section provides: This section explains which U.S. care settings are expected to generate analyzer placement, cartridge consumption, testing volumes, and future decentralized diagnostic adoption.

8. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By Technology

8.1. Overview
8.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
8.1.2. Electrochemical and Biosensor-Based Testing
8.1.2.1. Ion-Selective Electrode Technology
8.1.2.2. Amperometric Biosensors
8.1.2.3. Potentiometric Sensors
8.1.2.4. Other Electrochemical Detection Technologies
8.1.3. Molecular Diagnostics and Nucleic-Acid Amplification
8.1.3.1. Polymerase Chain Reaction
8.1.3.2. Rapid PCR
8.1.3.3. Isothermal Nucleic-Acid Amplification
8.1.3.4. Other Molecular Detection Technologies
8.1.4. Immunoassay Technology
8.1.4.1. Fluorescence Immunoassay
8.1.4.2. Chemiluminescent Immunoassay
8.1.4.3. Enzyme-Based Immunoassay
8.1.4.4. Other Immunological Detection Technologies
8.1.5. Microfluidic Lab-on-Cartridge Technology
8.1.5.1. Microfluidic Chip Systems
8.1.5.2. Centrifugal Disc Systems
8.1.5.3. Integrated Sample-to-Answer Cartridges
8.1.6. Optical, Imaging and Hybrid Detection Technologies
8.1.6.1. Optical Absorbance
8.1.6.2. Fluorescence Detection
8.1.6.3. Digital Imaging and Cell Analysis
8.1.6.4. Multi-Modal Hybrid Detection

What this section provides: This section evaluates the analytical technologies driving device performance, test-menu expansion, miniaturization, multiplexing capability, sample-to-answer automation, and competitive differentiation.

9. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Manufacturer Sales
9.1.2.1. Direct Hospital Procurement
9.1.2.2. Direct Laboratory and POC Department Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.3.1. System-Wide Platform Standardization Agreements
9.1.3.2. Multi-Year Cartridge and Consumable Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.4.1. National GPO Agreements
9.1.4.2. Regional and Health-System Purchasing Alliances
9.1.5. Distributor and Specialty Diagnostic Supplier Sales
9.1.5.1. National Diagnostic Distributors
9.1.5.2. Regional and Specialty Distributors
9.1.6. Reagent Rental, Instrument Placement and Managed-Service Models
9.1.6.1. Reagent Rental Agreements
9.1.6.2. Volume-Based Instrument Placement
9.1.6.3. Managed POC Testing Service Agreements

What this section provides: This section explains how U.S. multi-analyte POC systems and proprietary consumables are purchased, contracted, standardized, and financed across hospitals, IDNs, outpatient networks, and decentralized diagnostic settings.

10. U.S. Multi-Analyte Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional POC Testing Volume and Healthcare Infrastructure Analysis
10.1.4. Regional Hospital, Urgent-Care and Physician-Office Laboratory Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional CLIA-Waived Testing Adoption Analysis
10.1.7. Regional Multi-Analyte Platform Installed-Base Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Test Panel, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 U.S. states, enabling clients to identify testing-volume hubs, hospital and urgent-care clusters, decentralized diagnostic opportunities, technology adoption hotspots, procurement patterns, and state-level commercial opportunities.

11. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Intensity and Installed-Base Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Product Portfolio Benchmarking
11.5. Test Menu and Multiplexing Capability Benchmarking
11.6. CLIA-Waived Platform Benchmarking
11.7. Connectivity and Digital Ecosystem Benchmarking
11.8. Company Profiles

11.8.1. Abbott Laboratories
11.8.2. Siemens Healthineers
11.8.3. Roche Diagnostics
11.8.4. Danaher Corporation
11.8.5. Cepheid
11.8.6. bioMérieux
11.8.7. BioFire Diagnostics
11.8.8. QuidelOrtho Corporation
11.8.9. Werfen
11.8.10. Radiometer Medical
11.8.11. Nova Biomedical
11.8.12. QIAGEN
11.8.13. DiaSorin
11.8.14. Becton, Dickinson and Company
11.8.15. Sysmex Corporation
11.8.16. HORIBA Medical
11.8.17. EKF Diagnostics
11.8.18. PixCell Medical
11.8.19. ACON Laboratories
11.8.20. Sekisui Diagnostics
11.8.21. Trinity Biotech
11.8.22. PTS Diagnostics
11.8.23. Thermo Fisher Scientific
11.8.24. Visby Medical
11.8.25. MeMed

Note: Each company profile will include company overview, U.S. multi-analyte point-of-care testing portfolio, platform and assay positioning, installed-base strategy, consumables model, financial positioning, FDA and CLIA-waiver developments, partnerships, competitive strategy, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, platform positioning, installed-base intelligence, assay-menu comparisons, recurring consumable economics, innovation direction, and strategic intelligence on leading and emerging U.S. multi-analyte POC testing companies.

12. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Next-Generation Multiplex Molecular Diagnostics
12.2.2. Microfluidic Lab-on-Cartridge Platforms
12.2.3. Biosensor Miniaturization and Multi-Parameter Detection
12.2.4. AI-Assisted Diagnostic Interpretation
12.2.5. Connected POC Device Ecosystems
12.2.6. Digital Quality Management and Remote Fleet Administration
12.2.7. Multi-Marker Host-Response Diagnostics
12.3. Expansion of CLIA-Waived Multi-Analyte Testing
12.4. Future of Syndromic Point-of-Care Testing
12.5. Future of Acute-Care Multi-Parameter Blood Analysis
12.6. Emerging Business Models
12.6.1. Reagent Rental Models
12.6.2. Instrument Placement Models
12.6.3. Enterprise Diagnostic Platform Contracts
12.6.4. Subscription and Managed Diagnostic Services
12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. White-Space Opportunity Analysis
12.10. Market Outlook to 2035

What this section provides: This section prepares clients for future technology shifts, changing testing locations, emerging clinical applications, new business models, investment opportunities, and potential market-development scenarios through 2035.

13. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Multi-Analyte POC Device Manufacturers
13.2. Recommendations for Assay and Cartridge Developers
13.3. Recommendations for Hospitals and Integrated Delivery Networks
13.4. Recommendations for Urgent-Care and Retail Health Operators
13.5. Recommendations for Physician-Office Laboratory Networks
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Diagnostic Startups
13.9. Go-to-Market Strategy Considerations
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. CLIA-Waiver and Regulatory Commercialization Strategy
13.12. U.S. State-Level Market Entry Prioritization
13.13. Hospital and IDN Contracting Strategy
13.14. Pricing and Cartridge Economics Strategy

What this section provides: This section converts the market intelligence into actionable recommendations for product development, platform positioning, clinical evidence generation, regulatory strategy, hospital contracting, state-level expansion, channel development, and investment prioritization.

14. U.S. Multi-Analyte Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. Primary and Secondary Research Limitation
14.5. Forecasting Limitation
14.6. State-Level Market Estimation Limitation
14.7. Regulatory and Reimbursement Information Limitation
14.8. Legal Disclaimer
14.9. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope boundaries, data-use conditions, state-level modeling limitations, regulatory and reimbursement assumptions, forecasting limitations, and legal considerations.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Point-of-Care Turnaround-Time Value Matrix
TABLE 21: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Consumables and Recurring Revenue Economics
TABLE 23: U.S. Multi-Analyte Point-of-Care Testing Devices Market: POC Governance and Laboratory Oversight Matrix
TABLE 24: U.S. Multi-Analyte Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 25: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Analyzer Pricing Analysis
TABLE 28: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Cartridge and Reagent Pricing Analysis
TABLE 29: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 30: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 31: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Cartridge and Reagent Manufacturing Ecosystem
TABLE 32: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Digitalization and Connected POC Testing Impact
TABLE 33: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 34: U.S. Multi-Analyte Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 35: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CLIA Waiver Pathway Analysis
TABLE 36: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 37: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CPT Coding and Payment Considerations
TABLE 38: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CLIA Regulatory and Testing Complexity Landscape
TABLE 39: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 40: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Government Initiatives and Public Health Programs
TABLE 41: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 42: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Type Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Product Type
TABLE 44: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 45: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 46: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Handheld Multi-Analyte Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Portable and Compact Benchtop Multi-Analyte Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Cartridge-Based Multiplex Molecular Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Multi-Analyte Immunoassay Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Integrated Lab-on-Cartridge and Multi-Parameter Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Type CAGR Comparison, 2026–2035
TABLE 52: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Type Revenue Opportunity Matrix
TABLE 53: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Type Installed-Base and Consumables Opportunity Analysis
TABLE 54: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Type Competitive Intensity Analysis
TABLE 55: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Test Panel Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by Test Panel
TABLE 57: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Test Panel, 2021–2035 (US$ Billion)
TABLE 58: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Segment Share Analysis, by Test Panel, 2025 & 2035 (%)
TABLE 59: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Blood Gas, Electrolyte and Metabolite Panels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Multiplex Infectious-Disease Panels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Cardiometabolic Multi-Marker Panels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Hematology and Coagulation Panels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Specialty and Emerging Multi-Marker Panels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Test Panel CAGR Comparison, 2026–2035
TABLE 65: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Test Panel Clinical Utility Matrix
TABLE 66: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Test Panel Reimbursement and Utilization Matrix
TABLE 67: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Multiplex Panel Adoption Opportunity Analysis
TABLE 68: U.S. Multi-Analyte Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 69: Segment Dashboard; Definition and Scope, by End User
TABLE 70: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 71: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 72: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Urgent-Care Centers and Retail Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Physician-Office Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Ambulatory, Specialty and Post-Acute Care Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Community, Mobile and Decentralized Care Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Multi-Analyte Point-of-Care Testing Devices Market: End User CAGR Comparison, 2026–2035
TABLE 78: U.S. Multi-Analyte Point-of-Care Testing Devices Market: End User Testing Volume and Workflow Matrix
TABLE 79: U.S. Multi-Analyte Point-of-Care Testing Devices Market: End User Purchasing Criteria Analysis
TABLE 80: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Decentralized Care Adoption Opportunity Matrix
TABLE 81: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Technology Snapshot, 2025
TABLE 82: Segment Dashboard; Definition and Scope, by Technology
TABLE 83: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 84: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 85: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Electrochemical and Biosensor-Based Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Molecular Diagnostics and Nucleic-Acid Amplification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Immunoassay Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Microfluidic Lab-on-Cartridge Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Optical, Imaging and Hybrid Detection Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Technology CAGR Comparison, 2026–2035
TABLE 91: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Technology Maturity and Adoption Matrix
TABLE 92: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Sample-to-Answer Technology Benchmarking
TABLE 93: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Technology Innovation Opportunity Matrix
TABLE 94: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Procurement Channel Snapshot, 2025
TABLE 95: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 96: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 97: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 98: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Direct Manufacturer Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Distributor and Specialty Diagnostic Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Reagent Rental, Instrument Placement and Managed-Service Models Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Procurement Channel CAGR Comparison, 2026–2035
TABLE 104: U.S. Multi-Analyte Point-of-Care Testing Devices Market: IDN and GPO Contracting Dynamics
TABLE 105: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Reagent Rental and Instrument Placement Economics
TABLE 106: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Procurement Channel Opportunity Matrix
TABLE 107: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 108: Segment Dashboard; Definition and Scope, by Region
TABLE 109: U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 110: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 111: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional CAGR Comparison, 2026–2035
TABLE 112: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Healthcare Infrastructure and POC Adoption Matrix
TABLE 113: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 114: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 115: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 116: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 117: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Test Panel, 2021–2035 (US$ Billion)
TABLE 118: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 119: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 120: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 121: California Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Washington Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Arizona Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Colorado Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Oregon Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Utah Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Nevada Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: New Mexico Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Idaho Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Montana Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Wyoming Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Alaska Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Hawaii Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 135: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 136: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 137: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 138: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Test Panel, 2021–2035 (US$ Billion)
TABLE 139: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 140: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 141: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 142: New York Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Massachusetts Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: New Jersey Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Pennsylvania Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Connecticut Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Maine Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Vermont Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: New Hampshire Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Rhode Island Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Delaware Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 153: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 154: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 155: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 156: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Test Panel, 2021–2035 (US$ Billion)
TABLE 157: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 158: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 159: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 160: Texas Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Florida Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Georgia Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: North Carolina Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Tennessee Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: South Carolina Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Alabama Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Mississippi Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Louisiana Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Arkansas Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Kentucky Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Oklahoma Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 172: Virginia Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 173: Maryland Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 174: West Virginia Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 175: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 176: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 177: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 178: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 179: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Test Panel, 2021–2035 (US$ Billion)
TABLE 180: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 182: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 183: Illinois Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 184: Ohio Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 185: Michigan Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 186: Minnesota Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 187: Indiana Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 188: Wisconsin Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 189: Missouri Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 190: Iowa Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 191: Kansas Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 192: Nebraska Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 193: North Dakota Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 194: South Dakota Multi-Analyte Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 195: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 196: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 197: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 198: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 199: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Test Menu and Multiplexing Capability Benchmarking
TABLE 200: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CLIA-Waived Platform Benchmarking
TABLE 201: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Connectivity and Digital Ecosystem Benchmarking
TABLE 202: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 203: Abbott Laboratories: Company Profile
TABLE 204: Siemens Healthineers: Company Profile
TABLE 205: Roche Diagnostics: Company Profile
TABLE 206: Danaher Corporation: Company Profile
TABLE 207: Cepheid: Company Profile
TABLE 208: bioMérieux: Company Profile
TABLE 209: BioFire Diagnostics: Company Profile
TABLE 210: QuidelOrtho Corporation: Company Profile
TABLE 211: Werfen: Company Profile
TABLE 212: Radiometer Medical: Company Profile
TABLE 213: Nova Biomedical: Company Profile
TABLE 214: QIAGEN: Company Profile
TABLE 215: DiaSorin: Company Profile
TABLE 216: Becton, Dickinson and Company: Company Profile
TABLE 217: Sysmex Corporation: Company Profile
TABLE 218: HORIBA Medical: Company Profile
TABLE 219: EKF Diagnostics: Company Profile
TABLE 220: PixCell Medical: Company Profile
TABLE 221: ACON Laboratories: Company Profile
TABLE 222: Sekisui Diagnostics: Company Profile
TABLE 223: Trinity Biotech: Company Profile
TABLE 224: PTS Diagnostics: Company Profile
TABLE 225: Thermo Fisher Scientific: Company Profile
TABLE 226: Visby Medical: Company Profile
TABLE 227: MeMed: Company Profile
TABLE 228: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 229: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 230: U.S. Multi-Analyte Point-of-Care Testing Devices Market: CLIA-Waived Testing Expansion Outlook
TABLE 231: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Multiplex Molecular Diagnostics Outlook
TABLE 232: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Emerging Business Models and Trends
TABLE 233: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 234: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 235: U.S. Multi-Analyte Point-of-Care Testing Devices Market: White-Space Opportunity Analysis
TABLE 236: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 237: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Assay and Cartridge Developers
TABLE 238: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and IDNs
TABLE 239: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Urgent-Care and Retail Health Operators
TABLE 240: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Physician-Office Laboratories
TABLE 241: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 242: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 243: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 244: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 245: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 246: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Scope Limitation
TABLE 247: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Market Definition Limitation
TABLE 248: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 249: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 250: U.S. Multi-Analyte Point-of-Care Testing Devices Market: State-Level Market Estimation Limitation
TABLE 251: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 252: U.S. Multi-Analyte Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Multi-Analyte Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. Multi-Analyte Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Multi-Analyte Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. Multi-Analyte Point-of-Care Testing Devices Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Point-of-Care Turnaround-Time Value Framework
FIGURE 12: Hospital Capital Procurement Decision Framework
FIGURE 13: Consumables and Recurring Revenue Economics Framework
FIGURE 14: Value Chain Analysis
FIGURE 15: Supply Chain Analysis
FIGURE 16: PESTEL Analysis
FIGURE 17: Porter’s Five Forces Analysis
FIGURE 18: FDA Regulatory and CLIA Waiver Pathway Framework
FIGURE 19: CMS Reimbursement and CPT Payment Landscape
FIGURE 20: CLIA Testing Complexity Landscape
FIGURE 21: Connected POC Testing, LIS/EHR Integration and Cybersecurity Framework
FIGURE 22: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Product Type Segment CAGR Comparison, 2026–2035
FIGURE 25: Product Type Revenue and Installed-Base Opportunity Matrix
FIGURE 26: Product Type Competitive Intensity Matrix
FIGURE 27: Test Panel Segment Market Share Analysis, 2025 & 2035
FIGURE 28: Test Panel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Test Panel Segment CAGR Comparison, 2026–2035
FIGURE 30: Multi-Analyte Test Panel Clinical Utility Matrix
FIGURE 31: Multiplex Test Panel Growth Opportunity Matrix
FIGURE 32: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 33: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: End User Segment CAGR Comparison, 2026–2035
FIGURE 35: End User Workflow and Purchasing Criteria Matrix
FIGURE 36: Decentralized Care Adoption Opportunity Matrix
FIGURE 37: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Technology Segment CAGR Comparison, 2026–2035
FIGURE 40: Technology Maturity and Adoption Matrix
FIGURE 41: Sample-to-Answer Technology Innovation Roadmap
FIGURE 42: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 43: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Procurement Channel CAGR Comparison, 2026–2035
FIGURE 45: IDN, GPO and Direct Procurement Decision Framework
FIGURE 46: Reagent Rental and Instrument Placement Economics Framework
FIGURE 47: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 48: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: West Region U.S. Multi-Analyte Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 50: West Region Market Share Analysis by State, 2025
FIGURE 51: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: California Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Washington Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Arizona Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Colorado Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Oregon Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Utah Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Nevada Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: New Mexico Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Idaho Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Montana Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Wyoming Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Alaska Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Hawaii Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Northeast Region U.S. Multi-Analyte Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 66: Northeast Region Market Share Analysis by State, 2025
FIGURE 67: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: New York Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Massachusetts Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: New Jersey Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Pennsylvania Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Connecticut Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Maine Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Vermont Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Hampshire Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Rhode Island Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Delaware Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: South Region U.S. Multi-Analyte Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 79: South Region Market Share Analysis by State, 2025
FIGURE 80: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Texas Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Florida Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Georgia Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: North Carolina Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Tennessee Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Carolina Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Alabama Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Mississippi Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Louisiana Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Arkansas Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Kentucky Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Oklahoma Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Virginia Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Maryland Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: West Virginia Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Midwest Region U.S. Multi-Analyte Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 97: Midwest Region Market Share Analysis by State, 2025
FIGURE 98: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Illinois Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Ohio Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Michigan Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Minnesota Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Indiana Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Wisconsin Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Missouri Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Iowa Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Kansas Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Nebraska Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: North Dakota Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: South Dakota Multi-Analyte Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 112: Company Positioning Matrix
FIGURE 113: Key Player Product Portfolio Benchmarking
FIGURE 114: Test Menu and Multiplexing Capability Benchmarking
FIGURE 115: CLIA-Waived Platform Benchmarking
FIGURE 116: Connectivity and Digital Ecosystem Benchmarking
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: Multi-Analyte Point-of-Care Testing Innovation Roadmap
FIGURE 119: Installed-Base and Recurring Consumables Competitive Matrix
FIGURE 120: Future Market Scenario Analysis, 2026–2035
FIGURE 121: Disruptive Technologies Impact Matrix
FIGURE 122: Multiplex Molecular Diagnostics Adoption Roadmap
FIGURE 123: Microfluidic Lab-on-Cartridge Opportunity Map
FIGURE 124: CLIA-Waived Testing Expansion Roadmap
FIGURE 125: Emerging Business Model Evolution Framework
FIGURE 126: Investment Prioritization and White-Space Opportunity Matrix
FIGURE 127: Strategic Growth Roadmap for U.S. Multi-Analyte POC Testing Companies
FIGURE 128: Go-to-Market Strategy Framework
FIGURE 129: Product Positioning and Portfolio Expansion Framework
FIGURE 130: Hospital and IDN Contracting Strategy Framework
FIGURE 131: State-Level Commercial Expansion Prioritization Matrix
FIGURE 132: Report Scope and Disclaimer Framework